Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1981 3
1982 9
1983 14
1984 34
1985 39
1986 70
1987 59
1988 68
1989 102
1990 119
1991 133
1992 159
1993 172
1994 204
1995 191
1996 215
1997 217
1998 219
1999 244
2000 218
2001 251
2002 221
2003 209
2004 235
2005 266
2006 298
2007 276
2008 256
2009 265
2010 306
2011 340
2012 335
2013 300
2014 312
2015 302
2016 298
2017 282
2018 278
2019 270
2020 271
2021 251
2022 231
2023 199
2024 205
2025 230
2026 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,462 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for epirubicin
Search for Serirubicin instead (1 results)
Clinical pharmacokinetics of epirubicin.
Robert J. Robert J. Clin Pharmacokinet. 1994 Jun;26(6):428-38. doi: 10.2165/00003088-199426060-00002. Clin Pharmacokinet. 1994. PMID: 8070217 Review.
Importantly, epirubicin causes less cardiotoxicity than doxorubicin. There is extensive distribution of epirubicin into tissues and the elimination of the drug is predominantly biliary, with less than 15% of the drug excreted in the urine. ...Therefore, epirubici …
Importantly, epirubicin causes less cardiotoxicity than doxorubicin. There is extensive distribution of epirubicin into tissue …
Epirubicin. Clinical pharmacology and dose-effect relationship.
Robert J. Robert J. Drugs. 1993;45 Suppl 2:20-30. doi: 10.2165/00003495-199300452-00005. Drugs. 1993. PMID: 7693418 Review.
Glucuronide metabolites of epirubicin and epirubicinol are not active per se, but could divert epirubicin from free radical formation, which may induce cardiotoxic effects. ...Cumulative cardiac toxicity occurs for both epirubicin and doxorubicin, but the dos …
Glucuronide metabolites of epirubicin and epirubicinol are not active per se, but could divert epirubicin from free radical fo …
Epirubicin: a review of its intravesical use in superficial bladder cancer.
Onrust SV, Wiseman LR, Goa KL. Onrust SV, et al. Drugs Aging. 1999 Oct;15(4):307-33. doi: 10.2165/00002512-199915040-00006. Drugs Aging. 1999. PMID: 10582777 Review.
Intravesical prophylaxis with epirubicin was as effective as that with equivalent dosages of doxorubicin after TUR. Data are conflicting concerning the relative efficacy of intravesical epirubicin and bacillus Calmette-Guerin (BCG) in patients at intermediate risk o …
Intravesical prophylaxis with epirubicin was as effective as that with equivalent dosages of doxorubicin after TUR. Data are conflict …
Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
Khasraw M, Bell R, Dang C. Khasraw M, et al. Breast. 2012 Apr;21(2):142-9. doi: 10.1016/j.breast.2011.12.012. Epub 2012 Jan 17. Breast. 2012. PMID: 22260846 Free article. Review.
The anthracyclines commonly used in treatment of breast cancer are either epirubicin or doxorubicin. Epirubicin is an epimer of doxorubicin with important role in the chemotherapy treatment of both early and metastatic breast cancer. The efficacy of epirubicin …
The anthracyclines commonly used in treatment of breast cancer are either epirubicin or doxorubicin. Epirubicin is an epimer o …
Epirubicin in combination with the taxanes.
Trudeau M, Pagani O. Trudeau M, et al. Semin Oncol. 2001 Aug;28(4 Suppl 12):41-50. Semin Oncol. 2001. PMID: 11552229 Review.
The anthracyclines, and doxorubicin in particular, have been the most widely used drugs for advanced and metastatic breast cancer. Epirubicin shares the same spectrum of antitumor activity as doxorubicin, however, a therapeutic advantage of epirubicin is the higher …
The anthracyclines, and doxorubicin in particular, have been the most widely used drugs for advanced and metastatic breast cancer. Epirub …
[Epirubicin (4'-epi-adriamycin].
Tsukagoshi S. Tsukagoshi S. Gan To Kagaku Ryoho. 1990 Jan;17(1):151-9. Gan To Kagaku Ryoho. 1990. PMID: 2404456 Review. Japanese.
In non-clinical experiments, the effect of epirubicin on transplantable murine tumors was similar or superior to that of doxorubicin in rats and mice. ...Electrocardiographic and histopathological findings also disclosed that epirubicin exhibited a smaller effect on …
In non-clinical experiments, the effect of epirubicin on transplantable murine tumors was similar or superior to that of doxorubicin …
Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Plosker GL, Faulds D. Plosker GL, et al. Drugs. 1993 May;45(5):788-856. doi: 10.2165/00003495-199345050-00011. Drugs. 1993. PMID: 7686469 Review.
Recently, dose-intensive regimens of epirubicin have achieved high response rates in a number of malignancies including early and advanced breast cancer and lung cancer. ...In vitro and clinical studies have shown that, at equimolar doses, epirubicin is less myeloto …
Recently, dose-intensive regimens of epirubicin have achieved high response rates in a number of malignancies including early and adv …
Drugs ten years later: epirubicin.
Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, Demicheli R, Valagussa P. Bonadonna G, et al. Ann Oncol. 1993 May;4(5):359-69. doi: 10.1093/oxfordjournals.annonc.a058514. Ann Oncol. 1993. PMID: 8353070 Free article. Review. No abstract available.
Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
Kaklamani VG, Gradishar WJ. Kaklamani VG, et al. Clin Breast Cancer. 2003 Apr;4 Suppl 1:S26-33. doi: 10.3816/cbc.2003.s.012. Clin Breast Cancer. 2003. PMID: 12756076 Review.
The equimolar dose ratios of doxorubicin to epirubicin for myelosuppression and cardiotoxicity are 1:1.2 and 1:1.7-2.0, respectively. ...However, direct comparisons between doxorubicin and epirubicin in early-stage breast cancer have not been performed to date. In t …
The equimolar dose ratios of doxorubicin to epirubicin for myelosuppression and cardiotoxicity are 1:1.2 and 1:1.7-2.0, respectively. …
8,462 results